Filter
580
Filtered Results: 580
Text search:
COVID-19
and
pregnancy
Featured
Recommendations
76
New Publications
18
Language
Document type
Studies & Reports
215
Guidelines
172
Strategic & Response Plan
56
Fact sheets
49
Manuals
42
Situation Updates
13
Training Material
10
No document type
9
Infographics
7
Resource Platforms
3
Videos
2
Brochures
1
App
1
Countries / Regions
Global
59
India
22
Latin America and the Carribbean
21
South Africa
16
Brazil
15
Western and Central Europe
13
Russia
12
Syria
11
Ukraine
11
Nigeria
9
Kenya
9
South–East Asia Region
9
East and Southern Africa
8
Middle East and North Africa
8
Bangladesh
7
Malawi
7
Eastern Europe and Central Asia
6
South Sudan
5
Yemen
5
Africa
5
Congo, Democratic Republic of
4
Ethiopia
4
Haiti
4
Nepal
4
Afghanistan
4
Zambia
4
Western Pacific Region
4
Uganda
3
Philippines
3
Germany
3
Colombia
3
West and Central Africa
3
Venezuela
3
Ghana
2
Zimbabwe
2
Somalia
2
Pakistan
2
Lebanon
2
Mozambique
2
Argentina
2
Peru
2
Ecuador
2
Bolivia
2
Myanmar / Burma
2
Sri Lanka
2
Palestine
2
Laos
2
North America
2
Sierra Leone
1
Senegal
1
Côte d’Ivoire / Ivory Coast
1
USA
1
Cameroon
1
Turkey
1
Cambodia
1
Thailand
1
Rwanda
1
Indonesia
1
Sudan
1
Central African Republic
1
Namibia
1
Eswatini/ Swaziland
1
Honduras
1
Botswana
1
Mexico
1
Chile
1
Asia
1
Fiji
1
Eastern Europe
1
Congo-Brazzaville
1
Bulgaria
1
Vietnam
1
Jamaica
1
France
1
United Kingdom
1
Spain
1
Authors & Publishers
Publication Years
Category
Countries
216
Women & Child Health
53
Clinical Guidelines
46
Public Health
38
Key Resources
13
Capacity Building
10
Pharmacy & Technologies
4
Annual Report MEDBOX
1
Toolboxes
COVID-19
279
HIV
44
Caregiver
30
NCDs
24
Conflict
21
Mental Health
19
Planetary Health
17
Refugee
13
Rapid Response
10
TB
10
Global Health Education
10
Pharmacy
10
Natural Hazards
8
Health Financing Toolbox
7
NTDs
6
AMR
3
Disability
2
Zika
2
Ebola
1
Cholera
1
This second edition of the “living paper” contributes to the global knowledge on how countries are responding to the pandemic by documenting real-time actions in a key area of response – that is, social protection measures planned or implemented by governments.
For the purpose of this revie...
Pandemics and outbreaks have differential impacts on women and men. From risk of exposure and biological susceptibility to infection to the ...
Annals of Global Health, 87(1), p.43. DOI: http://doi.org/10.5334/aogh.3269;
The aim of this study was to examine the prevalence of mental health symptoms (anxiety, depression, and stress) in Bangladesh ... the factors associated with these symptoms during the COVID-19 pandemic.
They found that about 64%, 87%, and 61% of the respondents in Bangladesh reported high levels of depression, anxiety, and stress, respectively and this varied between divisions (regions), more in women, those who self-quarantined, and those that experienced classical symptoms of COVID-19. We think there is a need for mental health support in this population to minimise the long term effects.
The health and socioeconomic crisis triggered by the COVID-19 pandemic has hit the countries of Latin America hard ... laid bare the profound inequities about which numerous international, regional and national reports have sounded warnings in recent decades. In this context, the historical political and economic exclusion and marginalization of the more than 800 indigenous peoples in the region has been accentuated as a result of insufficient State responses to the crisis, which have not adequately considered the collective rights of these peoples and have had little cultural relevance.
This document provides an overview of the situation of indigenous peoples in the region in the face of the COVID-19 pandemic. It analyses both the State’s and indigenous peoples’ own responses to the crisis, as well as offering a set of recommendations to rectify the neglect of these peoples in the management of the pandemic, centring on their collective rights.
While much progress has been achieved over the past year, the Region of the Americas has stubbornly remained the epicenter of the COVID-19 pandemic. PAHO is launching its 2021 ...-19 Response Strategy and Donor Appeal to continue supporting Latin American and Caribbean countries and territories in their fight against COVID-19. This document outlines PAHO’s regional strategy for the year 2021 to sustain and scale-up the response to COVID‑19 pandemic in the Americas, suppress the community transmission of the virus and mitigate the longer-term health impact of the pandemic.
US$ 239 million is needed to support critical response efforts in the Americas between 1 January and 31 December 2021
he pandemic has produced an unprecedented economic and social crisis, and it could generate a food, humanitarian, and political crisis if urgent me...
Published:February 02, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00234-8
This guidance note aims to provide practical support to service providers operating Women and Girls Safe Spaces (WGSS) on how to adapt programming in the context of the COVID-... pandemic.
This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 ha...
Forcibly Displaced Myanmar National / Rohingya Refugee Response.
This document gives guidance for medical providers to understand the care of both healthy and COVID suspect or confirmed patients wh...
The COVID-19 pandemic has exacerbated and added yet another layer of vulnerability to an already dire web of vulnerabilities of girls in the Africa...
In the wake of the Covid‑19 Pandemic, parts of the public health system at increased risk of reduced efficiency include healthcare services for women and children. This in turn could reverse all the progress achieved over the ye...
RESULTS: Between 76 and 97% of the PHCS offered RMCAH services before the lockdown. Except in antenatal, delivery and adolescent care, there was a decline of between 2 ... 6% in all the services during the lockdown and up to 10% decline after the lockdown with variation across and within States. During the lockdown. Full-service delivery was reported by 75.2% whereas 24.8% delivered partial services. There was a significant reduction in clients' utilization of the services during the lockdown, and the difference between States before the pandemic, during, and after the lockdown. Reported difficulties during the lockdown included stock-out of drugs (25.7%), stock-out of contraceptives (25.1%), harassment by the law enforcement agents (76.9%), and transportation difficulties (55.8%). Only 2% of the PHCs reported the availability of gowns, 18% had gloves, 90.1% had hand sanitizers, and a temperature checker was available in 94.1%. Slightly above 10% identified clients with symptoms of COVID-19.
CONCLUSIONS: The large proportion of PHCs who provided RMCAH services despite the lockdown demonstrates resilience. Considering the several difficulties reported, and the limited provision of primary protective equipment more effort by the government and non-governmental agencies is recommended to strengthen delivery of sexual and reproductive health in primary health centres in Nigeria during the pandemic.
14 January 2021
This practical guide can be used to help countries monitor and analyse the impact of COVID-19 on essential health services to info...
SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns ...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-.... This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
Brazil ́s response is taking place in strict compliance with the International Health Regulations (IHR) 2005.
Brazil created the Emergency Operations Center (COE) and immediately notified WHO when the first case in Brazilian territory
was confirm...
